Is Arcellx, Inc. (ACLX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.8% / 30% | 6.7% / 30% | 0.0% / 30% | 108.67% / 5% | ✗ NOT HALAL |
| DJIM | 0.8% / 33% | 6.7% / 33% | 0.0% / 33% | 108.67% / 5% | ✗ NOT HALAL |
| MSCI | 8.6% / 33% | 74.6% / 33% | 0.0% / 33% | 108.67% / 5% | ✗ NOT HALAL |
| S&P | 0.8% / 33% | 6.7% / 33% | 0.0% / 33% | 108.67% / 5% | ✗ NOT HALAL |
| FTSE | 8.6% / 33% | 74.6% / 33% | 0.0% / 50% | 108.67% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -3850.2% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -53.4% | |
| Return on Assets (ROA) | -24.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$210M |
| Free Cash Flow | -$213M |
| Total Debt | $52M |
| Debt-to-Equity | 12.9 |
| Current Ratio | 4.4 |
| Total Assets | $604M |
Price & Trading
| Last Close | $114.61 |
| 50-Day MA | $91.40 |
| 200-Day MA | $78.53 |
| Avg Volume | 2.2M |
| Beta | 0.2 |
|
52-Week Range
$47.86
| |
About Arcellx, Inc. (ACLX)
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Arcellx, Inc. (ACLX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Arcellx, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Arcellx, Inc.'s debt ratio?
Arcellx, Inc.'s debt ratio is 0.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 8.6%.
What are Arcellx, Inc.'s key financial metrics?
Arcellx, Inc. has a market capitalization of $6.7B, and revenue of $22M. Return on equity stands at -53.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.